Point of care diagnostic devices and the move to decentralized testing
Why point of care diagnostics matter now
Point of care diagnostic devices move testing closer to the patient, rather than routing every specimen through a central laboratory workflow. Their value is not speed alone. It is the ability to connect a test result with an immediate clinical decision, such as starting treatment, isolating an infectious patient, adjusting anticoagulation, confirming pregnancy, or escalating care.
As the U.S. Food and Drug Administration has noted in its digital diagnostics work, non-laboratory-based testing expanded rapidly during the SARS-CoV-2 era and is expected to keep growing. For manufacturers, providers and buyers, the question is no longer whether decentralized testing is useful. It is where a specific test is accurate, practical and safe enough to replace or complement laboratory testing.
This article reviews the device categories, regulatory considerations, implementation criteria and limitations that matter most for healthcare organizations evaluating point of care testing. For more coverage of related technologies, visit our Diagnostic Devices section.
What counts as a point of care diagnostic device
A point of care diagnostic device is typically an in vitro diagnostic system used at or near the place where care is delivered. It may be a small lateral-flow test, a cartridge-based molecular analyzer, a handheld blood chemistry system, a connected glucose meter, or a benchtop instrument placed in an emergency department, physician office, ambulance, pharmacy or community clinic.
Size is not the defining feature. A compact device may still require trained operators, calibration, quality control and defined environmental conditions. At the same time, a simple visually read test can create risk if staff are not trained, specimens are collected incorrectly, or results are not documented in the medical record. In practical terms, point of care testing should be evaluated as a clinical workflow, not just as a product purchase.
Public health organizations have also emphasized the access role of diagnostics. The World Health Organization promotes the Essential Diagnostics List as a reference for countries developing national lists of priority in vitro diagnostic tests. That perspective matters for point of care devices because decentralized testing is often most valuable where transport delays, staffing shortages or limited laboratory infrastructure prevent timely diagnosis.
Common device categories and where they fit
The point of care market is broad, and each category solves a different operational problem. A respiratory molecular platform in an emergency department has little in common with a urine pregnancy test in a primary care office, even though both may fall under point of care diagnostics.
| Device category | Typical use setting | Main value | Key limitation |
|---|---|---|---|
| Rapid immunoassay and lateral-flow tests | Clinics, pharmacies, urgent care, field screening | Fast, low-complexity results for infectious disease, pregnancy and selected biomarkers | Performance may vary with specimen quality, timing of infection and operator technique |
| Handheld or benchtop chemistry analyzers | Emergency departments, intensive care, ambulances, operating rooms | Immediate blood gas, electrolyte, lactate or metabolic information | Requires cartridge management, quality control and integration with clinical records |
| Glucose and chronic disease monitoring systems | Hospitals, outpatient clinics, home care | Frequent monitoring and rapid therapy adjustment | Accuracy can be affected by user behavior, strip handling and interfering conditions |
| Cartridge-based molecular systems | Hospitals, urgent care, outbreak response, remote clinics | Higher analytical sensitivity and multiplex detection near the patient | Higher cost, supply dependence and more demanding contamination controls |
| Coagulation and cardiac marker devices | Emergency care, anticoagulation clinics, perioperative settings | Supports time-sensitive decisions such as anticoagulation adjustment or cardiac triage | Results must be interpreted within clinical context and may require confirmatory testing |
The strongest deployments usually start with a clear clinical use case. If a faster result changes the patient pathway, point of care testing can deliver real value. If the result still waits for manual review, phone calls, duplicate entry or delayed follow-up, the device may simply move the bottleneck from the laboratory to the care site.
Regulation and quality separate useful devices from risky shortcuts
Point of care does not mean unregulated or informal testing. In the United States, the Clinical Laboratory Improvement Amendments framework applies to facilities or sites that test human specimens for health assessment or to diagnose, prevent or treat disease, as summarized by the Centers for Disease Control and Prevention. The FDA categorizes tests by complexity under CLIA, and its public databases list commercially marketed tests that have been categorized, including waived tests and currently waived analytes.
CLIA waiver is about complexity, not clinical importance
Many point of care tests are described as CLIA-waived, but the term is often misunderstood. A waived test is considered simple enough and low enough risk of erroneous result, under defined conditions, to be performed outside a moderate- or high-complexity laboratory environment. It does not mean the result is clinically minor, immune from error, or free from quality obligations.
Manufacturers may seek a CLIA waiver by application when a test initially categorized as moderate complexity can be shown to meet waiver criteria. For buyers, the practical question is whether the exact test system, intended use, specimen type and setting match the authorization or clearance. Substituting specimen types, changing workflows, using off-label interpretation, or skipping quality control can move a site away from the conditions under which the test was evaluated.
Quality systems are still required at the care site
Point of care programs need governance. This includes operator training, competency checks, lot-to-lot verification where appropriate, environmental monitoring, internal and external quality control, documentation of corrective actions, and procedures for critical results. Internationally, many laboratories and accreditation bodies now reference ISO 15189:2022 for medical laboratory quality and competence, including requirements relevant to point of care testing governance.
The quality challenge is organizational. In a central laboratory, testing is performed by a defined group of trained professionals. In decentralized testing, operators may include nurses, medical assistants, pharmacists, paramedics or other care staff whose primary job is not laboratory science. That makes device usability, lockout features, clear prompts, barcoding and connectivity more than convenience features; they are safeguards against preventable errors.
Technology trends shaping the next generation
The current direction of point of care diagnostics is toward more sensitive assays, more connected workflows and broader testing environments. These trends are promising, but they also raise expectations for validation, cybersecurity, interoperability and clear clinical pathways.
Multiplex and molecular testing are moving closer to the patient
Cartridge-based nucleic acid amplification systems have made molecular diagnostics more practical outside traditional molecular laboratories. Multiplex respiratory panels, sexually transmitted infection testing and selected antimicrobial resistance applications are examples of areas where near-patient molecular testing can shorten time to action. The trade-off is cost, instrument maintenance, supply chain dependence, contamination control and responsible interpretation of multi-pathogen results.
Connectivity is becoming part of diagnostic performance
A result that remains on a device screen is operationally weak. Modern point of care systems increasingly need bidirectional connectivity with electronic health records, laboratory information systems and public health reporting channels. The FDA’s work on connected diagnostics reflects this shift: reliable digital reporting, standardized data capture and integration into clinical workflows are now central to safe decentralized testing. See also: clinical equipment.
Connectivity also creates new responsibilities. Patient matching, audit trails, software updates, cybersecurity controls and downtime procedures should be reviewed before adoption. A fast test can still create clinical risk if the result is assigned to the wrong patient or never reaches the treating clinician.
Home-use and self-collection models are expanding carefully
Home-use diagnostics and self-collection kits overlap with point of care testing because they move part of the diagnostic process outside the conventional clinic. FDA consumer guidance on home-use tests emphasizes that such tests can support healthcare decisions but should not replace appropriate medical evaluation. That caveat matters. Home and self-collection models can improve access, privacy and screening uptake, but positive, negative or invalid results may still require clinical follow-up or laboratory confirmation depending on the test and condition.
How healthcare buyers should evaluate devices
Adoption decisions should begin with the clinical pathway. A device that looks attractive on turnaround time may fail if staffing, documentation, reimbursement or confirmatory testing have not been planned. The following criteria are more useful than comparing devices by headline speed alone:
- Intended use and authorization: Confirm the exact claims, specimen types, user setting and CLIA categorization for the test system.
- Clinical impact: Identify the decision that changes because the result is available sooner.
- Analytical and clinical performance: Review sensitivity, specificity, precision, interference data and performance in the intended population.
- Workflow fit: Consider hands-on time, cartridge storage, sample preparation, maintenance, cleaning and operator steps.
- Quality control: Define control frequency, documentation, corrective action and responsibility for oversight.
- Connectivity: Require secure result transfer, patient identification safeguards and integration with existing systems where possible.
- Total cost: Include cartridges, controls, service, training, data interfaces, waste handling and staff time, not only instrument price.
- Supply resilience: Assess single-source consumables, shelf life, cold-chain needs and manufacturer support.
The central buying question is whether the device improves the full diagnostic process. Faster testing is valuable only when the result is trusted, documented and acted on.
Limits that should not be ignored
Point of care testing can reduce delays, but it can also decentralize error. Common risks include insufficient training, informal workarounds, expired reagents, poor specimen collection, undocumented results, duplicate testing and overreliance on a single negative result. These risks are not arguments against point of care diagnostics. They are reasons to implement them with the same seriousness applied to central laboratory testing.
Clinical interpretation is another limitation. A diagnostic device produces information, not a complete diagnosis. Respiratory tests depend on timing and specimen quality. Cardiac markers require symptom history, serial testing and electrocardiographic findings. Glucose results may be affected by physiological and technical factors. Infectious disease tests may need confirmation in low-prevalence settings or when the result conflicts with clinical presentation.
Healthcare organizations should also avoid assuming that every decentralized test reduces cost. Some point of care programs save money by shortening visits, preventing admissions, improving isolation decisions or reducing follow-up losses. Others increase spending if cartridges are expensive, utilization is poorly controlled, or central laboratory testing is duplicated. A small pilot with workflow measurement can show whether the proposed deployment actually improves care.
Frequently asked questions
Are point of care diagnostic devices the same as home tests?
No. Home tests are intended for consumer or patient use, while many point of care devices are intended for trained personnel in healthcare settings such as clinics, hospitals, pharmacies or urgent care centers. Some technologies overlap, but the authorization, labeling, training assumptions and reporting responsibilities can differ.
Does CLIA-waived mean anyone can run the test anywhere?
No. A CLIA-waived test must still be used under the conditions specified by its labeling and within an appropriate testing site framework. Facilities performing human specimen testing in the United States generally need the correct CLIA certificate type, and staff must follow the manufacturer’s instructions and site quality procedures.
When is central laboratory testing still preferable?
Central laboratory testing may be preferable when high throughput, complex panels, specialist interpretation, confirmatory testing, advanced quality systems or lower per-test costs are more important than immediate turnaround. In many care models, point of care and central laboratory testing work best as complementary services.
What is the biggest implementation mistake?
The most common mistake is buying a device before designing the workflow. Training, quality control, patient identification, result reporting, clinical follow-up and supply management should be planned before testing begins, not after problems appear.
What should manufacturers prioritize for future devices?
Manufacturers should prioritize clear intended-use claims, robust usability, automated quality safeguards, secure connectivity, transparent performance data and practical workflows for non-laboratory operators. The next stage of competition is likely to be defined as much by implementation reliability as by analytical technology.
